Epistasis and Pleiotropy Affect the Modularity of the Genotype-Phenotype Map of Cross-Resistance in HIV-1

被引:12
|
作者
Polster, Robert [1 ]
Petropoulos, Christos J. [2 ]
Bonhoeffer, Sebastian [1 ]
Guillaume, Frederic [1 ,3 ]
机构
[1] Swiss Fed Inst Technol, Inst Integrat Biol, Univ Str 16, Zurich, Switzerland
[2] Monogram Biosci, San Francisco, CA USA
[3] Univ Zurich, Dept Evolutionary Biol & Environm Studies, Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
mutation; genetic integration; M-matrix; G-matrix; IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; GENETIC ARCHITECTURE; DROSOPHILA-MELANOGASTER; DIFFERENTIAL EPISTASIS; CAENORHABDITIS-ELEGANS; MANDIBULAR MORPHOLOGY; QUANTITATIVE TRAITS; DRUG-RESISTANCE; COMPLEX TRAITS;
D O I
10.1093/molbev/msw206
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The genotype-phenotype (GP) map is a central concept in evolutionary biology as it describes the mapping of molecular genetic variation onto phenotypic trait variation. Our understanding of that mapping remains partial, especially when trying to link functional clustering of pleiotropic gene effects with patterns of phenotypic trait co-variation. Only on rare occasions have studies been able to fully explore that link and tend to show poor correspondence between modular structures within the GP map and among phenotypes. By dissecting the structure of the GP map of the replicative capacity of HIV-1 in 15 drug environments, we provide a detailed view of that mapping from mutational pleiotropic variation to phenotypic co-variation, including epistatic effects of a set of amino-acid substitutions in the reverse transcriptase and protease genes. We show that epistasis increases the pleiotropic degree of single mutations and provides modularity to the GP map of drug resistance in HIV-1. Moreover, modules of epistatic pleiotropic effects within the GP map match the phenotypic modules of correlated replicative capacity among drug classes. Epistasis thus increases the evolvability of cross-resistance in HIV by providing more drug-and class-specific pleiotropic profiles to the main effects of the mutations. We discuss the implications for the evolution of cross-resistance in HIV.
引用
收藏
页码:3213 / 3225
页数:13
相关论文
共 50 条
  • [21] Predicting Bevirimat resistance of HIV-1 from genotype
    Heider, Dominik
    Verheyen, Jens
    Hoffmann, Daniel
    BMC BIOINFORMATICS, 2010, 11
  • [22] KINETIC CHARACTERIZATION AND CROSS-RESISTANCE PATTERNS OF HIV-1 PROTEASE MUTANTS SELECTED UNDER DRUG PRESSURE
    GULNIK, SV
    SUVOROV, LI
    LIU, BS
    YU, B
    ANDERSON, B
    MITSUYA, H
    ERICKSON, JW
    BIOCHEMISTRY, 1995, 34 (29) : 9282 - 9287
  • [23] Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP)
    Gonzalez, Emmanuel
    Ballana, Ester
    Clotet, Bonaventura
    Este, Jose A.
    AIDS, 2011, 25 (13) : 1575 - 1583
  • [24] Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations
    Schapiro, JM
    Winters, MA
    Lawrence, J
    Merigan, TC
    AIDS, 1999, 13 (03) : 359 - 365
  • [25] Network Modules of the Cross-Species Genotype-Phenotype Map Reflect the Clinical Severity of Human Diseases
    Han, Seong Kyu
    Kim, Inhae
    Hwang, Jihye
    Kim, Sanguk
    PLOS ONE, 2015, 10 (08):
  • [26] Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment
    Roukos, Dimitrios H.
    Katsios, Christos
    Liakakos, Theodore
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2010, 10 (05) : 541 - 545
  • [27] GENOTYPE AND PHENOTYPE CHARACTERIZATION OF THE HIV-1 TRANSMITTED FROM MOTHER TO INFANT
    MO, HM
    ZHU, TF
    CAO, YZ
    GU, GL
    KOUP, RA
    BORKOWSKY, W
    HO, DD
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 98 - 98
  • [28] Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance
    Parkin, NT
    Chappey, C
    Petropoulos, CJ
    AIDS, 2003, 17 (07) : 955 - 961
  • [29] Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy
    Morand-Joubert, L
    Charpentier, C
    Poizat, G
    Chêne, G
    Dam, E
    Raguin, G
    Taburet, AM
    Girard, PM
    Hance, AJ
    Clavel, F
    ANTIVIRAL THERAPY, 2006, 11 (02) : 143 - 154
  • [30] Cross-resistance profile of the novel lysine-containing HIV-1 protease inhibitor PL-100
    Sévigny, G
    Stranix, BR
    Parkin, N
    Lie, Y
    Yelle, J
    ANTIVIRAL THERAPY, 2004, 9 (04) : U27 - U27